ClinicalTrials.gg
Active, not recruitingNCT05155423Updated Nov 10, 2026

A Prospective Study of Performing MRI Simulation in Treatment Position in Spinal Stereotactic Body Radiation Therapy

An observational study in Spinal Metastases, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by M.D. Anderson Cancer Center · Observational

How we know

Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
21
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 135 studies in Neoplasm Metastasis by M.D. Anderson Cancer Center — 21 open to participants now, 46 under way, 7 of them phase 3. Neoplasm Metastasis · M.D. Anderson Cancer Center.

Enrollment
10th of 10
21 · median 167
Started
2018
with 9 others
Observational
10 of 135
2 open now
Primary completion
2027-02
later than 15 of 45 live
Registered
125th of 135
by date

Among the 135 studies in Neoplasm Metastasis by M.D. Anderson Cancer Center, this one is the 10th largest by enrollment of the 10 observational ones that give a count, is one of 10 that started in 2018, is one of 10 observational ones, reaches primary completion later than 15 of the 45 other live ones, and was the 125th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

21 of the 135 studies in Neoplasm Metastasis by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Where they have run

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 135 studies in Neoplasm Metastasis by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

To learn the usefulness of performing MRI scans in different positions and learn the best practice for spinal stereotactic body radiation therapy (spinal SBRT) planning and dose delivery.

Read the detailed description

1. Objectives

  1. Assess the feasibility of performing MRI scans in the treatment position for accurate treatment planning and dose delivery in spinal stereotactic body radiation therapy (spinal SBRT).
  2. Characterize the improved accuracy of image fusion between MRI and CT and its dosimetric impact when performing MRI scans in treatment position in spinal SBRT.
  3. Assess the ability of MRI simulation to accurately target extended spinal targets beyond the current targeting limitations (>3 consecutive vertebral body levels)
  4. Optimize the workflow of using MRI simulation in treatment planning and dose delivery.
03

Conditions studied

  • Spinal Metastases

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

MDACC Cancer Participants

Eligibility criteria

3.1. Inclusion Criteria

  1. Greater than or equal to 18 years of age
  2. confirmed diagnosis of cancer, including, but not limited to non-small cell lung cancer, breast, prostate, renal cell, melanoma, gastrointestinal, sarcoma, thyroid, head and neck primary, and carcinoma of unknown primary
  3. Signed
  4. Willing to undergo 2 MRI simulations in one or multiple sessions, one with immobilization device, and the other without.
  5. Patients undergoing spinal SBRT 3.2. Exclusion Criteria

a. Patient with a relative or absolute to MRI (such as pacemaker, etc.) b. Patients with significant instrumentation or cement at the site of interest causing artifact c. Inability to tolerate with immobilization device for greater than 30 minutes

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
21 participants (actual)
Patient registry
No

Groups and cohorts

  • group 1

    patient using mask for immobilization

    Other: mask for immobilization

  • group 2

    patients using Elekta BodyFix

    Other: Elekta BodyFix

Interventions

  • Othermask for immobilization

    mask for immobilization

  • OtherElekta BodyFix

    Elekta BodyFix

06

What researchers measure

Primary outcomes

  1. Performing MRI scans in the treatment position for accurate treatment planning.

    Time frame: through study completion, an average of 1 year

  2. Performing MRI scans in the treatment position for dose delivery in spinal stereotactic body radiation therapy (spinal SBRT).

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2018 (actual). Primary completion is estimated for Feb 2027, 105 months after the start.

Of 211 non-industry observational studies under Neoplasm Metastasis, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 172. This study's planned 105 months is above that.

Counting every sponsor, half of 242 studies reached it within 66 months; a quarter within 35 and three quarters within 172.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion May 2026 → Feb 2027 and completion May 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2021
First posted
Dec 13, 2021
StartActual
Apr 21, 2018
Primary completionEst.
Feb 2, 2027was May 2026
CompletionEst.
Feb 2, 2027was May 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 24, 2026→Feb 2, 2027
Nov 10, 2026
Study completion
May 24, 2026→Feb 2, 2027
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion May 24, 2026→Feb 2, 2027
    Study completion May 24, 2026→Feb 2, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05155423
Collaborators
Elekta Limited
Responsible party
Sponsor
First posted
Dec 13, 2021
Start date
Apr 21, 2018
Primary completion
Feb 2, 2027 (estimated)
Completion
Feb 2, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Amol Ghia, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion